Therapeutic monoclonal antibodies are among the most effective biotherapeutics to date. An
important aspect of antibodies is their ability to bind antigen while at the same time recruit …

Critical quality attributes (CQA) are physical, chemical, biological or microbiological
properties or characteristics that must be within an appropriate limit, range or distribution to …

Recombinant human IgG antibodies (hIgGs) completely devoid of binding to Fcγ receptors
(FcγRs) and complement protein C1q, and thus with abolished immune effector functions …

The tutorial introduces the readers to the fundamentals of antibody pharmacokinetics (PK) in
the context of drug development. Topics covered include an overview of antibody …

The antibody Fc region regulates antibody cytotoxic activities and serum half-life. In a
therapeutic context, however, the cytotoxic effector function of an antibody is often not …

Therapeutic antibodies (IgG-type) contain several post-translational modifications (PTMs)
whereby introducing a large heterogeneity, both structural and functional, into this class of …

Monoclonal antibodies (mAbs) are an important therapeutic class with complex
pharmacology and interdependent pharmacokinetic (PK) and pharmacodynamics (PD) …

N-glycosylation is one of major post-translational modifications in nature, and it is essential
for protein structure and function. As hydrophilic moieties of glycoproteins, N-glycans play …

The spread of tau pathology correlates with cognitive decline in Alzheimer's disease. In vitro,
tau antibodies can block cell-to-cell tau spreading. Although mechanisms of anti-tau function …

Since the approval of the first monoclonal antibody (mAb) in 1986, a huge effort has been
made to guarantee safety and efficacy of therapeutic mAbs. As of July 2021, 118 mAbs are …